Ecamsule
Anthelios, Capital Soleil (ecamsule) is a small molecule pharmaceutical. Ecamsule was first approved as Anthelios sx on 2006-07-21.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Anthelios, Anthelios sx, Capital soleil
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avobenzone
+
Ecamsule
+
Octocrylene
+
Titanium dioxide
Labels
FDA
EMA
Show 32 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| photosensitivity disorders | — | D010787 | L57.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Ecamsule |
| INN | ecamsule |
| Description | Ecamsule (USAN, trade name Mexoryl SX, INCI terephthalylidene dicamphor sulfonic acid) is an organic compound which is added to many sunscreens to filter out UVA rays. It is a benzylidene camphor derivative, many of which are known for their excellent photostability.
|
| Classification | Small molecule |
| Drug class | camphorsulfonic acid derivatives used as UVA sunscreens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)C2CCC1(CS(=O)(=O)O)C(=O)C2=Cc1ccc(C=C2C(=O)C3(CS(=O)(=O)O)CCC2C3(C)C)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 92761-26-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989850 |
| ChEBI ID | — |
| PubChem CID | 6442003 |
| DrugBank | — |
| UNII ID | M94R1PM439 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use